

Stefano Mariani

ESPERIENZA PROFESSIONALE

- **Giugno 2023 - Agosto 2025** **SPECIALISTA ONCOLOGO**

Azienda Ospedaliera Universitaria CAGLIARI
S.C. Oncologia Medica
- **Novembre 2022- Presente** **CORSO DI DOTTORATO IN MEDICINA MOLECOLARE E TRANSLAZIONALE**

Università di Cagliari
- **Dicembre 2017- Gennaio 2023** **SPECIALIZZAZIONE ONCOLOGIA MEDICA**

Scuola di Specializzazione in Oncologia Medica - Università di Cagliari
Specialista in Oncologia Medica (50/50 cum laude) con la tesi:
"Identificazione e caratterizzazione di nuovo target terapeutico nel colangiocarcinoma"
- **Gennaio 2022-Dicembre 2022** **INTERNSHIP**

C.I.M.A. (Centro di Investigazione Medica Applicata)
Dipartimento di Epatologia dell'Università di Navarra
Pamplona (Spagna)
- **Agosto 2014-Dicembre 2017** **MEDICO DI MEDICINA GENERALE GUARDIA MEDICA**

Azienda Sanitaria Regionale - USL Umbria 1

EDUCAZIONE

- **Febbraio 2014** **ABILITAZIONE PROFESSIONALE**

University of Perugia
- **Ottobre 2007-Ottobre 2013** **CORSO DI LAUREA IN MEDICINA E CHIRURGIA**

Facoltà di Medicina e Chirurgia - Università degli Studi di Perugia
Laureato (110/110 cum laude) discutendo la tesi:
"Chemioipertermia: revisione della letteratura e presentazione dell'esperienza dell'Università di Perugia"
- **Novembre 2012 - Maggio 2013** **INTERNSHIP**

M.I.S.O. (Medicina Interna e Scienze Oncologiche)
Azienda Ospedaliera Universitaria di Perugia
- **Settembre 2011-Luglio 2012** **PROGRAMMA ERASMUS**

First Faculty of Medicine - Charles University - Praga (CZ)
- **Maggio 2011- Settembre 2011** **SCHOLARSHIP**

Tutor della Facoltà di Medicina e Chirurgia - Università di Perugia

ALTRO

Gennaio 2018 - Maggio 2021

SUB-INVESTIGATOR IN PROTOCOLLI CLINICI DI FASE III E IV

Study TIDE-A
Study 20190009
Study 20190294
Study IMbrave050 - WO41535
Study INVIDIa-2
Study TATA
Study ONC-2016-01
Study SOLSTICE
Study 2017-01
Study IMPROVE
Study IMbrave150

AWARDS

Giugno 2021

MERIT AWARD ASCO 2021

"Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer."

CONOSCENZE LINGUISTICHE

SPEAKING READING WRITING

ITALIAN	native		
ENGLISH	B2	B2	B2
SPANISH	B1	B2	A2

PUBBLICAZIONI

Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment

D. Spanu, A. Pretta, E. Lai, M. Persano, C. Donisi, S. Mariani, M. Dubois, M. Migliari, G. Saba, P. Ziranu, V. Pusceddu, M. Puzzone, G. Astara, M. Scartozzi

World J Hepatol 2022 July 27; 14(7): 1319-1332, DOI: 10.4254/wjh.v14.i7.1319

How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world.

Pretta A, Spanu D, Mariani S, Liscia N, Ziranu P, Pusceddu V, Puzzone M, Massa E, Scartozzi M, Lai

E. World J Clin Oncol. 2022 May 24;13(5):417-422. doi: 10.5306/wjco.v13.i5.417. PMID: 35662988; PMCID: PMC9153079.

Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients

S. Mariani, M. Puzzone, R. Giampieri, P. Ziranu, V. Pusceddu, C. Donisi, M. Persano, G. Pinna, E. Cimbro, A. Parrino, D. Spanu, A. Pretta, E. Lai, N. Liscia, A. Lupi, E. Giglio, G. Palomba, M. Casula, M. Pisano, G. Palmieri and M. Scartozzi

Front. Oncol., 21 April 2022 | <https://doi.org/10.3389/fonc.2022.852583>

The Difficult Task of Diagnosing Depression in Elderly People with Cancer: A Systematic Review

E. Massa, C. Donisi, N. Liscia, C. Madeddu, V. Impera, S. Mariani, M. Scartozzi and Eleonora Lai **Clinical Practice & Epidemiology in Mental Health, DOI: 10.2174/1745017902117010295, 2021, 17, (Suppl-1, M7) 295-306**

Molecular-driven treatment for biliary tract cancer: the promising turning point

M. Persano, M. Puzzoni, P. Ziranu, V. Pusceddu, E. Lai, A. Pretta, C. Donisi, G. Pinna, D. Spanu, E. Cimbri, A. Parrino, N. Liscia, S. Mariani, M. Dubois, M. Migliari, M. Scartozzi
Expert Rev Anticancer Ther 21 Nov 2021 DOI: 10.1080/14737140.2021.1982699

Liquid biopsy driven anti-EGFR rechallenge in metastatic colorectal cancer

M. Puzzoni, R. Giampieri, S. Mariani, P. Ziranu, V. Pusceddu, C. Donisi, M. Persano, G. Pinna, E. Cimbri, A. Parrino, A. Pretta, E. Lai, N. Liscia, A. Lupi, E. Giglio, G. Palomba, M. Casula, M. Pisano, G. Palmieri, M. Scartozzi

Annals of Oncology 2021, VOL. 32, SUPPLEMENT 5, S543-S544, Sept. 01, 2021

New horizons in metastatic colorectal cancer: Role of CD44 expression

P. Ziranu, V. Aimola, A. Pretta, G. Cerrone, M. Persano, N. Liscia, M. Dubois, M. Migliari, F. Sarais, E. Cimbri, A. Parrino, D. Spanu, S. Mariani, C. Donisi, G. Pinna, V. Pusceddu, M. Puzzoni, E. Lai, G. Faa, M. Scartozzi

Annals of Oncology 2021, VOL. 32, SUPPLEMENT 5, S543-S544, Sept. 01, 2021

Lymphocyte to monocyte ratio as a prognostic factor in stage IV pancreatic ductal adenocarcinoma naive patients before gemcitabine-nab-paclitaxel chemotherapy

A. Pretta, C. Donisi, M. Persano, G. Pinna, E. Cimbri, A. Parrino, M. Migliari, M. Dubois, N. Liscia, S. Mariani, E. Lai, M. Puzzoni, V. Pusceddu, P. Ziranu, M. Scartozzi

Annals of Oncology 2021, VOL. 32, SUPPLEMENT 3, S142, July 01, 2021

Influence of anti-diabetic medications on the outcomes of patients with pancreatic ductal adenocarcinoma and type 2 diabetes mellitus

A. Pretta, G. Pinna, C. Donisi, M. Persano, E. Cimbri, A. Parrino, M. Migliari, M. Dubois, N. Liscia, S. Mariani, E. Lai, V. Pusceddu, M. Puzzoni, P. Ziranu, M. Scartozzi

Annals of Oncology 2021, VOL. 32, SUPPLEMENT 3, S142, July 01, 2021

Concomitant RAS and BRAF mutations: Impact on overall survival and progression free survival in metastatic colorectal cancer patients

A. Pretta, M. Persano, G. Pinna, C. Donisi, E. Cimbri, A. Parrino, M. Migliari, M. Dubois, S. Mariani, N. Liscia, E. Lai, V. Pusceddu, M. Puzzoni, P. Ziranu, M. Scartozzi

Annals of Oncology 2021, VOL. 32, SUPPLEMENT 3, S142, July 01, 2021

Uncovering key targets of success for immunotherapy in pancreatic cancer.

Pretta A, Lai E, Persano M, Donisi C, Pinna G, Cimbri E, Parrino A, Spanu D, Mariani S, Liscia N, Dubois M, Migliari M, Impera V, Saba G, Pusceddu V, Puzzoni M, Ziranu P, Scartozzi M.

Expert Opin Ther Targets.2021Nov;25(11):987-1005.Epub 2021 Dec 13.

doi: 10.1080/14728222.2021.2010044. PMID: 34806517.

Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study

E. Lai, M. Puzzoni, P. Ziranu, C. Cremolini, S. Lonardi, M. Banzi, S. Mariani, N. Liscia, S. Cinieri, M. Dettori, M. Mencoboni, F. Nappo, G. Piacentini, R. Labianca, G. Zucchelli, A. Boccaccino, V. Conca, V. Pusceddu, A. Zaniboni, M. Scartozzi, On behalf of GISCAD (Italian Group for the Study of Gastrointestinal Tumors)

Clinical Colorectal Cancer, Vol. 000, No.xxx, 1-10 © 2021 Elsevier Inc. All rights reserved. ghts reserved. <https://doi.org/10.1016/j.clcc.2021.07.008>

Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers

R. Zhang, M. Puzzoni, **S. Mariani**, Y. Zheng, N. Liscia, Y. Guo, C. Donisi, Y. Liu, V. Impera, W. Fang, M. Scartozzi

CancerScience Volume 112, Issue 12 p. 4819-4833 <https://doi.org/10.1111/cas.15139>

Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer.

S. Mariani, M. Puzzoni, N. Liscia, V. Impera, A. Pretta, S. Tolu, A.G. Pireddu, M. Persano, F. Musio, C. Donisi, G. Pinna, E. Lai, L. Demurtas, P. Ziranu, V. Pusceddu, M. Pisano, G. Palomba, M. Casula, G. Palmieri, M. Scartozzi;

Journal of Clinical Oncology 2021 39:15_suppl, 3577-3577

BRCA-mutant pancreatic ductal adenocarcinoma: a different species or just a mutant?

Lai E., Ziranu P., Spanu D., Dubois M., Pretta A., Tolu S., Camera S., Liscia N., **Mariani S.**, Persano M., Migliari M., Donisi C., Demurtas L., Pusceddu V., Puzzoni M., Scartozzi M.

British Journal of Cancer (2021) 125:1321-1332; <https://doi.org/10.1038/s41416-021-01469-9>

The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment

P. Ziranu, E. Lai, M. Schirripa, M. Puzzoni, M. Persano, A. Pretta, G. Munari, N. Liscia, V. Pusceddu, F. Loupakis, L. Demurtas, M. Libertini, **S. Mariani**, M. Migliari, M. Dubois, R. Giampieri, G. Sotgiu, A.P. Dei Tos, S. Lonardi, A. Zaniboni, M. Fassan, M. Scartozzi

Target Onco. 2021 May 10. doi: 10.1007/s11523-021-00816-3

Combining Immunotherapy with Anti-angiogenic Therapy: The New Standard of Care for Hepatocellular Cancer?

Dubois M., Persano M., Balconi F., Donisi C., Impera V., Liscia N., **Mariani S.**, Migliari M., Musio F., Pinna G., Pireddu A., Pretta A., Saba G., Spanu D., Tolu S., Demurtas L., Puzzoni M., Ziranu P., Lai E., Astaro G., Scartozzi M.

Journal of Clinical Oncology and Therapeutics. Vol. 3, Issue 1. doi: 10.47275/2690-5663-117. ISSN 2690-5663.

Immunecheckpoint Inhibitors in the treatment of HCC.

C. Donisi, M. Puzzoni, P. Ziranu, E. Lai, **S. Mariani**, G. Saba, V. Impera, M. Dubois, M. Persano, M. Migliari, A. Pretta, N. Liscia, G. Astaro, M. Scartozzi.

Front. Oncol., 07 January 2021. doi: 10.3389/fonc.2020.601240

Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?

E. Lai, G. Astaro, P. Ziranu, A. Pretta, M. Migliari, M. Dubois, C. Donisi, **S. Mariani**, N. Liscia, V. Impera, M. Persano, S. Tolu, F. Balconi, G. Pinna, D. Spanu, A. Pireddu, G. Saba, S. Camera, F. Musio, M. Puzzoni, V. Pusceddu, C. Madeddu, A. Casadei Gardini, M. Scartozzi.

Crit Rev Oncol Hematol. 2021 Jan;157:103167. Epub 2020 Nov 12. doi: 10.1016/j.critrevonc.2020.103167. PMID: 33271389

Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer

E. Lai, N. Liscia, C. Donisi, **S. Mariani**, S. Tolu, A. Pretta, M. Persano, G. Pinna, F. Balconi, A. Pireddu, V. Impera, M. Dubois, M. Migliari, D. Spanu, G. Saba, S. Camera, F. Musio, P. Ziranu, M. Puzzoni, L. Demurtas, V. Pusceddu, M. Dettori, E. Massa, F. Atzori, M. Dessì, G. Astara, C. Madeddu, M. Scartozzi

Cancers (Basel). 2020 May 13;12(5):1214. doi: 10.3390/cancers12051214.

Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients?

M. Puzzoni, P. Ziranu, L. Demurtas, E. Lai, **S. Mariani**, N. Liscia, P. Soro, A. Pretta, V. Impera, S. Camera, F. Musio, M. Persano, C. Donisi, S. Tolu, F. Balconi, M. Scartozzi.

FutureOncol.2020Jan;16(2):4337-4339.doi:10.2217/fon-2019-0624.Epub2019Dec 3.

New therapeutic targets in pancreatic cancer

Lai E, Puzzoni M, Ziranu P, Pretta A, Impera V, **Mariani S**, Liscia N, Soro P, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Pireddu A, Demurtas L, Pusceddu V, Camera S, Sclafani F, Scartozzi M.

Cancer Treat Rev. 2019 Dec;81:101926. doi: 10.1016/j.ctrv.2019.101926. Epub 2019 Nov 11.

Real-life data on the peri-operative FLOT regimen in in locally advanced resectable gastric/GEJ adenocarcinoma.

S. Camera, F. Musio, V. Impera, A. Pretta, **S. Mariani**, N. Liscia, P. Soro, S. Tolu, M. Persano, F. Balconi, C. Donisi, A. Pireddu, E. Lai, M. Puzzoni, G. Astara, P. Ziranu, M. Scartozzi.

Tumori Journal, Volume 105, number 6S, November 2019. Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM). Abstract n°B39

Retrospective survival analysis in metastatic pancreatic cancer patients affected by type 2 diabete mellitus.

A. Pretta, P. Ziranu, E. Lai, A. Casadei Gardini, M. Puzzoni, G. Orsi, **S. Mariani**, E. Molinaro, N. Liscia, L. Riggi, V. Pusceddu, G. Rovesti, V. Impera, S. Camera, F. Musio, P. Soro, L. Demurtas, G. Astara, K. Andrikou, S. Cascinu, M. Scartozzi.

Tumori Journal, Volume 105, number 6S, November 2019. Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM). Abstract and Poster n°B10

Safety and efficacy of immunotherapy in elderly patients with NSCLC: our experience.

S. Tolu, E. Massa, F. Balconi, S. Camera, A. Pretta, V. Impera, N. Liscia, M. Persano, C. Donisi, **S. Mariani**, E. Lai, G. Astara, P. Ziranu, C. Madeddu, M. Scartozzi.

Tumori Journal, Volume 105, number 6S, November 2019. Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM). Abstract n°D56

The management of biliary tract cancer: a new prognostic score system.

P. Ziranu, A. Pretta, K. Andrikou, E. Lai, L. Faloppi, G. Astara, F. Leone, **S. Mariani**, L. Fornaro, N. Liscia, C. Vivaldi, P. Soro, E. Sperti, R. Filippi, V. Pusceddu, L. Demurtas, M. Puzzoni, S. Cascinu, M. Scartozzi.

TumoriJournal, Vol.105,Num6S,Nov.2019. Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM). Abst.andPoster n°B08

Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab.

E. Lai, M. Schirripa, M. Puzzoni, F. Loupakis, P. Ziranu, A. Pretta, R. Giampieri, S. Mariani, N. Liscia, P. Soro, V. Pusceddu, G. Astara, V. Impera, S. Camera, F. Musio, A. Zaniboni, M. Fassan, S. Lonardi, V. Zagonel, M. Scartozzi.

Annals of Oncology, Volume 30, Issue Supplement_5, October 2019, mdz246.078, <https://doi.org/10.1093/annonc/mdz246.078>

A new prognostic score for biliary tract cancer: a multicenter experience.

P. Ziranu, E. Lai, A. Casadei Gardini, A. Pretta, L. Faloppi, K. Andrikou, G. Astara, G. Orsi, V. Impera, S. Mariani, N. Liscia, P. Soro, F. Musio, S. Camera, S. Tolu, C. Madeddu, E. Massa, V. Pusceddu, L. Demurtas, M. Puzzoni, S. Cascinu, M. Scartozzi.

Annals of Oncology, Volume 30, Issue Supplement_4, July 2019, mdz155.331, <https://doi.org/10.1093/annonc/mdz155.331>

Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine.

S. Mariani, P. Soro, N. Liscia, F. Balconi, S. Camera, C. Donisi, V. Impera, F. Musio, M. Persano, A. Pireddu, A. Pretta, S. Tolu, V. Pusceddu, E. Lai, L. Faloppi, L. Demurtas, P. Ziranu, M. Puzzoni, M. Scartozzi.

Annals of Oncology, Volume 30, Issue Supplement_4, July 2019, mdz155.229, <https://doi.org/10.1093/annonc/mdz155.229>

Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience.

A. Pretta, E. Lai, N. Liscia, V. Impera, S. Camera, F. Musio, S. Mariani, P. Soro, M. Persano, C. Donisi, S. Tolu, F. Balconi, F. Atzori, M. Dessì, E. Massa, C. Madeddu, V. Pusceddu, G. Astara, L. Demurtas, M. Puzzoni, P. Ziranu, M. Scartozzi.

Annals of Oncology, Volume 30, Issue Supplement_4, July 2019, mdz155.295,

Multidisciplinary management of cancer pain and breakthrough cancer pain: our center experience.

E. Lai, A. Pretta, V. Impera, G. Astara, M.C. Deidda, P. Ziranu, N. Liscia, S. Camera, A. Pireddu, S. Mariani, M. Persano, F. Musio, M. Puzzoni, L. Demurtas, V. Pusceddu, F. Atzori, M. Dessì, C. Madeddu, E. Massa, G. Finco, M. Scartozzi.

Tumori Journal. Abstract book of the 20th National Congress of Italian Association of Medical oncology (AIOM) 16-18 November, 2018 – Rome, Italy. Vol. 104 Number 4S November 2018. Abstract e poster n° M12

Efficacy, toxicity and quality of life of weekly chemotherapy regimen in elderly patients with gynaecological cancer.

S. Camera, M. Persano, V. Impera, E. Lai, N. Liscia, S. Mariani, F. Musio, A.G. Pireddu, A. Pretta, S. Tolu, E. Massa, C. Madeddu, G. Astara, P. Ziranu, A. Cubeddu, V. Mais, M. Peiretti, A. Proto, M. Scartozzi

Tumori Journal. Abstract book of the 20th National Congress of Italian Association of Medical oncology (AIOM) 16-18 November, 2018 – Rome, Italy. Vol. 104 Number 4S November 2018. Abstract n° H08

P53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab.

M. Puzzoni, L. Demurtas, P. Ziranu, E. Lai, R. Giampieri, L. Faloppi, A. Mandolesi, C. Cremolini, G. Masi, F. Gelsomino, **S. Mariani**, A. Cubeddu, L. Casula, N. Liscia, V. Pusceddu, C. Antoniotti, F. Meriggi, A. Zaniboni, A. Falcone, S. Cascinu, M. Scartozzi

Abstract e Poster P-209, ESMO 20th World Congress on Gastrointestinal Cancer (Barcellona, 20-23 Giugno 2018)

BRAF-mutant colorectal cancer, a different breed evolving.

E. Lai, A. Pretta, V. Impera, **S. Mariani**, R. Giampieri, L. Casula, V. Pusceddu, P. Coni, D. Fanni, M. Puzzoni, L. Demurtas, P. Ziranu, G. Faa, M. Scartozzi.

Expert Review of Molecular Diagnostics. 30 April 2018